자이어 테라퓨틱스(GYRE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $7.27 (+1.25%), 시가총액 $0.68B, 52주 최저~최고 $6.55 ~ $11.40.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In
자이어 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
자이어 테라퓨틱스의 현재 주가는 $7.27 (+1.25%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
자이어 테라퓨틱스의 시가총액은 약 $0.68B입니다.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company